Diana Davis

Diana Davis is an Emmy award-winning journalist and senior news anchor at KAIT-TV in Jonesboro, Arkansas. She has been honored with the National Academy of Television Arts and Sciences' Silver Circle award for her distinguished service within the industry for over 25 years.

Biography:  https://www.kait8.com/page/diana-davis/

46%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a poor reputation for journalistic standards and is not considered a reliable news source.

Bias

75%

Examples:

  • The author has a personal connection to the topic of Alzheimer's disease as her mother was diagnosed with it. This bias is evident in the way she describes her own experiences and emotions related to the diagnosis.
  • There are no logical fallacies or contradictions found in this article.

Conflicts of Interest

0%

Examples:

No current examples available.

Contradictions

0%

Examples:

No current examples available.

Deceptions

50%

Examples:

  • The author misrepresents the mechanism of action of Lecanemab by stating that it is a game-changer in regard to its mechanism of action when it's not true.
  • The author states that Lecanemab has been shown to slow down cognitive decline in patients with mild dementia from Alzheimer's disease which implies that it can be considered as a treatment rather than just symptomatic relief.

Recent Articles

Revolutionary Jab and Medication Show Promising Results in Preventing Alzheimer's Disease

Revolutionary Jab and Medication Show Promising Results in Preventing Alzheimer's Disease

Broke On: Sunday, 31 March 2024 A revolutionary jab and a medication called Leqembi are undergoing trials for Alzheimer's disease. The new vaccine aims to stop damage before it occurs, while the medication slows progression in early stages of dementia. Both have mild side effects and could be widely available within five years if successful in clinical trials.